Lipid raft composition changes in synaptic neurodegeneration

Analysis ID: SDA-2026-04-01-gap-lipid-rafts-2026-04-01 | Date: 2026-04-01 | Status: completed

Question

Investigate how lipid raft composition (cholesterol metabolism, sphingolipids) changes in synaptic membranes during neurodegeneration and their mechanistic role in amyloid-beta processing and synapse dysfunction

Hypotheses Generated (7)

1. Selective Acid Sphingomyelinase Modulation Therapy (0.83)

Target Gene: SMPD1

Partial inhibition of acid sphingomyelinase (SMPD1) to rebalance sphingomyelin/ceramide ratios in synaptic lipid rafts, preventing ceramide-induced synaptic dysfunction while maintaining essential membrane fluidity using allosteric modulators.

Dimension Scores

Mechanistic Plausibility: 0.85
Evidence Strength: 0.80
Novelty: 0.70
Feasibility: 0.90
Therapeutic Potential: 0.85
Druggability: 0.95
Safety Profile: 0.75
Competitive Landscape: 0.80
Data Availability: 0.85
Reproducibility: 0.85

2. Membrane Cholesterol Gradient Modulators (0.81)

Target Gene: ABCA1/LDLR/SREBF2

Compounds that create selective cholesterol depletion in amyloidogenic raft domains while preserving cholesterol in synaptic raft domains through differential targeting of cholesterol transport proteins.

Dimension Scores

Mechanistic Plausibility: 0.80
Evidence Strength: 0.85
Novelty: 0.75
Feasibility: 0.85
Therapeutic Potential: 0.80
Druggability: 0.90
Safety Profile: 0.70
Competitive Landscape: 0.75
Data Availability: 0.90
Reproducibility: 0.80

3. CYP46A1 Overexpression Gene Therapy (0.77)

Target Gene: CYP46A1

Targeted neuronal overexpression of cholesterol 24-hydroxylase (CYP46A1) to enhance brain cholesterol efflux and normalize lipid raft composition, reducing cholesterol-driven BACE1 clustering in rafts.

Dimension Scores

Mechanistic Plausibility: 0.90
Evidence Strength: 0.85
Novelty: 0.95
Feasibility: 0.60
Therapeutic Potential: 0.90
Druggability: 0.65
Safety Profile: 0.60
Competitive Landscape: 0.85
Data Availability: 0.75
Reproducibility: 0.70

4. Ganglioside Rebalancing Therapy (0.73)

Target Gene: ST3GAL2/ST8SIA1

Therapeutic modulation of ganglioside composition in synaptic membranes to restore optimal GM1/GD1a ratios that support neuroprotective raft organization while reducing ganglioside species that promote amyloid-β aggregation.

Dimension Scores

Mechanistic Plausibility: 0.70
Evidence Strength: 0.65
Novelty: 0.80
Feasibility: 0.75
Therapeutic Potential: 0.70
Druggability: 0.75
Safety Profile: 0.85
Competitive Landscape: 0.80
Data Availability: 0.60
Reproducibility: 0.70

5. Sphingomyelin Synthase Activators for Raft Remodeling (0.66)

Target Gene: SGMS1/SGMS2

Selective activation of sphingomyelin synthase to increase sphingomyelin content in synaptic membranes, counteracting pathological ceramide accumulation and restoring optimal raft fluidity for synaptic function.

Dimension Scores

Mechanistic Plausibility: 0.75
Evidence Strength: 0.70
Novelty: 0.85
Feasibility: 0.45
Therapeutic Potential: 0.75
Druggability: 0.40
Safety Profile: 0.65
Competitive Landscape: 0.90
Data Availability: 0.55
Reproducibility: 0.60

6. Flotillin-1 Stabilization Compounds (0.55)

Target Gene: FLOT1

Pharmacological enhancement of flotillin-1 expression and stability to reinforce beneficial lipid raft scaffolding that supports synaptic plasticity while preventing pathological raft clustering.

Dimension Scores

Mechanistic Plausibility: 0.60
Evidence Strength: 0.50
Novelty: 0.95
Feasibility: 0.25
Therapeutic Potential: 0.65
Druggability: 0.20
Safety Profile: 0.50
Competitive Landscape: 0.95
Data Availability: 0.40
Reproducibility: 0.45

7. Palmitoylation-Targeted BACE1 Trafficking Disruptors (0.49)

Target Gene: BACE1

Small molecules that specifically block BACE1 palmitoylation to prevent its targeting to lipid rafts without affecting global palmitoylation, relocalizing BACE1 away from APP-enriched raft domains.

Dimension Scores

Mechanistic Plausibility: 0.70
Evidence Strength: 0.60
Novelty: 0.80
Feasibility: 0.30
Therapeutic Potential: 0.40
Druggability: 0.35
Safety Profile: 0.30
Competitive Landscape: 0.20
Data Availability: 0.75
Reproducibility: 0.50

Debate Transcript

Full 4-round debate (Theorist → Skeptic → Expert → Synthesizer) available in analysis data.